NIFTY 50 22795.9 ▼ (0.51%)
NIFTY NEXT 50 60466.8 ▼ (0.94%)
NIFTY 100 23274.05 ▼ (0.59%)
NIFTY MIDCAP 100 50486.2 ▼ (1.32%)
NIFTY SMALLCAP 100 15636.9 ▼ (0.7%)
NIFTY SMALLCAP 250 14683.4 ▼ (0.57%)
NIFTY MIDCAP SELECT 11198.9 ▼ (1.69%)
NIFTY TOTAL MARKET 11634.25 ▼ (0.67%)
NIFTY BANK 48981.2 ▼ (0.72%)
SENSEX 75311.06 ▼ (0.56%)
BSE BANKEX 55718.18 ▼ (0.82%)

MEDICO REMEDIES LIMITED’s Quarterly Result and Earnings Report for Q4(Mar 2024) : Sales increased by 47.62 % in YoY and increased by 38.8 % in QoQ

May 10, 2024May 10, 2024| adminadmin| 0 Comments| 5:15 pm
Image is loading
Categories:

Share the post "MEDICO REMEDIES LIMITED’s Quarterly Result and Earnings Report for Q4(Mar 2024) : Sales increased by 47.62 % in YoY and increased by 38.8 % in QoQ"

  • Facebook
  • LinkedIn
  • X
  • Tumblr
  • WhatsApp
  • TelegramTelegram
  • Email

Highlights

  • Sales over the Year and quarter: The company experienced a substantial growth of 47.62 % in the past year, substantial increase in net sales/revenue by 38.8 %.
  • Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 1080 %. Marginal increase in other income during this quarter, up by 110.71%.
  • Profit over the Year and quarter: Significant improvement in profitability for MEDICO REMEDIES LIMITED. Notable increase of 75.48 % in net profit Year to Year, MEDICO REMEDIES LIMITED’s profitability increased by 114.46 % in this quarter.
  • EPS over the Year and quarter: EPS increased by 76.19 % Year to Year. EPS increased by 117.65 % in previous quarter. Positive impact on shareholders.

The comprehensive analytics outlining the performance and outlook of MEDICO REMEDIES LIMITED”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 27.992 Cr Rs. 29.772 Cr Rs. 41.323 Cr + 38.8 % + 47.62 %
Expenses Rs. 24.83 Cr Rs. 27.04 Cr Rs. 36.67 Cr + 35.61 % + 47.68 %
Operating Profit Rs. 3.16 Cr Rs. 2.73 Cr Rs. 4.65 Cr + 70.33 % + 47.15 %
OPM % 11.29 % 9.17 % 11.25 % + 2.08 % -0.04 %
Other Income Rs. 0.05 Cr Rs. 0.28 Cr Rs. 0.59 Cr + 110.71 % + 1080 %
Interest Rs. 0.21 Cr Rs. 0.22 Cr Rs. 0.25 Cr + 13.64 % + 19.05 %
Depreciation Rs. 0.73 Cr Rs. 0.72 Cr Rs. 0.74 Cr + 2.78 % + 1.37 %
Profit before tax Rs. 2.27 Cr Rs. 2.07 Cr Rs. 4.25 Cr + 105.31 % + 87.22 %
Tax % 22.31 % 29.96 % 27 % -2.96 % + 4.69 %
Net Profit Rs. 1.77 Cr Rs. 1.45 Cr Rs. 3.1 Cr + 113.79 % + 75.14 %
EPS in Rs Rs. 0.21 Rs. 0.17 Rs. 0.37 + 117.65 % + 76.19 %


Today, we’re looking at MEDICO REMEDIES LIMITED’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 47.62 %. However, it did see a marginal increase of 38.8 % from the previous quarter. Expenses ticked up slightly by 35.61 % quarter-on-quarter, aligning with the annual rise of 47.68 %. Operating profit, while up 47.15 % compared to last year, faced a quarter-on-quarter increase of 70.33 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.04 %, but an expansion of 2.08 % sequentially. Other income rose by 110.71 % compared to the last quarter, despite an annual growth of 1080 %. Interest expenses surged remarkably by 13.64 % from the previous quarter, yet the year-over-year increase remains at a moderate 19.05 %. Depreciation costs climbed by 2.78 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 1.37 %. Profit before tax grew annually by 87.22 % but saw an increase from the preceding quarter by 105.31 %.
Tax expenses as a percentage of profits increased slightly by 4.69 % compared to last year, with a more notable quarter-on-quarter decrease of -2.96 %. Net profit rose by 75.14 % year-on-year but experienced a 113.79 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 76.19 % but a quarterly rise of 117.65 %. In summary, MEDICO REMEDIES LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

Metrics Previous Year Previous Quarter Current Quarter Quarter to Quarter Difference Year to Year Difference
Sales Rs. 27.992 Cr Rs. 29.772 Cr Rs. 41.323 Cr + 38.8 % + 47.62 %
Expenses Rs. 24.83 Cr Rs. 27.04 Cr Rs. 36.67 Cr + 35.61 % + 47.68 %
Operating Profit Rs. 3.16 Cr Rs. 2.73 Cr Rs. 4.65 Cr + 70.33 % + 47.15 %
Net Profit Rs. 1.77 Cr Rs. 1.45 Cr Rs. 3.1 Cr + 113.79 % + 75.14 %
EPS in Rs Rs. 0.21 Rs. 0.17 Rs. 0.37 + 117.65 % + 76.19 %


In reviewing MEDICO REMEDIES LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 47.62 % year-on-year growth, however, there was a minor increase of 38.8 % from the previous quarter. Expenses rose by 47.68 % compared to the previous year, with a 35.61 % increase quarter-on-quarter. Operating Profit surged by 47.15 % annually, and saw a 70.33 % increase from the last quarter.
Net Profit showed yearly increase of 75.14 %, and experienced a 113.79 % increase from the previous quarter. Earnings Per Share (EPS) rose by 76.19 % annually, however rose by 117.65 % compared to the last quarter. In essence, while MEDICO REMEDIES LIMITED exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.

[my_shortcode1 values=”MEDICO REMEDIES LIMITED”]

Related Post